Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study).
<h4>Background</h4>Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in MTX-naïve patients. Howev...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0322621 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331503394193408 |
|---|---|
| author | Mitsuhiro Akiyama Toshihiko Hidaka Motohide Kaneko Satoshi Ito Hiroaki Taguchi Tomonori Ishii Shuji Asai Shintaro Hirata Kei Ikeda Katsuya Suzuki Naoki Kato Yuko Kaneko |
| author_facet | Mitsuhiro Akiyama Toshihiko Hidaka Motohide Kaneko Satoshi Ito Hiroaki Taguchi Tomonori Ishii Shuji Asai Shintaro Hirata Kei Ikeda Katsuya Suzuki Naoki Kato Yuko Kaneko |
| author_sort | Mitsuhiro Akiyama |
| collection | DOAJ |
| description | <h4>Background</h4>Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in MTX-naïve patients. However, comparisons in patients with an inadequate response to MTX remain unclear. This study aims to evaluate the efficacy and safety of FIL plus MTX versus FIL monotherapy in patients with rheumatoid arthritis who have an inadequate response to MTX.<h4>Methods and analysis</h4>FAITHFUL (Filgotinib Add-on versus swITcH to Filgotinib in patients with rheUmatoid arthritis who inadequateLy responded to methotrexate) study is a phase IV multicenter, prospective, open-label, randomized controlled trial. Patients with a history of inadequate response to at least 8 weeks of MTX and moderate or high disease activity will be assessed for eligibility at 10 centers in Japan. A history of Janus kinase inhibitor use is an exclusion criterion, but prior use of biologic agents is not considered. Enrolled patients will be randomly assigned in a 1:1 ratio to either the group adding FIL (Add-on group) or the group switching to FIL monotherapy (Switch group). The target sample size is 120 participants. The primary endpoint is the change in DAS28-CRP from baseline to week 24, aiming to assess if the Switch group is non-inferior to the Add-on group. Safety will be evaluated by assessing the incidence of adverse events.<h4>Ethics and dissemination</h4>The study has received approval from the Certified Review Board of Keio University Hospital (N20230002) and adheres to the principles outlined in the Declaration of Helsinki and good clinical practice standards. Prior to enrollment, all participants provide written informed consent. The findings from this study are intended to be submitted for publication in relevant peer-reviewed journals.<h4>Trial registration</h4>The trial was registered at Japan Registry of Clinical Trials (jRCTs031230673). |
| format | Article |
| id | doaj-art-b2bf8d5eb542404dbc78a940509cefda |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-b2bf8d5eb542404dbc78a940509cefda2025-08-20T03:46:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01205e032262110.1371/journal.pone.0322621Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study).Mitsuhiro AkiyamaToshihiko HidakaMotohide KanekoSatoshi ItoHiroaki TaguchiTomonori IshiiShuji AsaiShintaro HirataKei IkedaKatsuya SuzukiNaoki KatoYuko Kaneko<h4>Background</h4>Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in MTX-naïve patients. However, comparisons in patients with an inadequate response to MTX remain unclear. This study aims to evaluate the efficacy and safety of FIL plus MTX versus FIL monotherapy in patients with rheumatoid arthritis who have an inadequate response to MTX.<h4>Methods and analysis</h4>FAITHFUL (Filgotinib Add-on versus swITcH to Filgotinib in patients with rheUmatoid arthritis who inadequateLy responded to methotrexate) study is a phase IV multicenter, prospective, open-label, randomized controlled trial. Patients with a history of inadequate response to at least 8 weeks of MTX and moderate or high disease activity will be assessed for eligibility at 10 centers in Japan. A history of Janus kinase inhibitor use is an exclusion criterion, but prior use of biologic agents is not considered. Enrolled patients will be randomly assigned in a 1:1 ratio to either the group adding FIL (Add-on group) or the group switching to FIL monotherapy (Switch group). The target sample size is 120 participants. The primary endpoint is the change in DAS28-CRP from baseline to week 24, aiming to assess if the Switch group is non-inferior to the Add-on group. Safety will be evaluated by assessing the incidence of adverse events.<h4>Ethics and dissemination</h4>The study has received approval from the Certified Review Board of Keio University Hospital (N20230002) and adheres to the principles outlined in the Declaration of Helsinki and good clinical practice standards. Prior to enrollment, all participants provide written informed consent. The findings from this study are intended to be submitted for publication in relevant peer-reviewed journals.<h4>Trial registration</h4>The trial was registered at Japan Registry of Clinical Trials (jRCTs031230673).https://doi.org/10.1371/journal.pone.0322621 |
| spellingShingle | Mitsuhiro Akiyama Toshihiko Hidaka Motohide Kaneko Satoshi Ito Hiroaki Taguchi Tomonori Ishii Shuji Asai Shintaro Hirata Kei Ikeda Katsuya Suzuki Naoki Kato Yuko Kaneko Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). PLoS ONE |
| title | Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). |
| title_full | Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). |
| title_fullStr | Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). |
| title_full_unstemmed | Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). |
| title_short | Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). |
| title_sort | protocol filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate a multicenter prospective open label randomized controlled trial faithful study |
| url | https://doi.org/10.1371/journal.pone.0322621 |
| work_keys_str_mv | AT mitsuhiroakiyama protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT toshihikohidaka protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT motohidekaneko protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT satoshiito protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT hiroakitaguchi protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT tomonoriishii protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT shujiasai protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT shintarohirata protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT keiikeda protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT katsuyasuzuki protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT naokikato protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy AT yukokaneko protocolfilgotinibinadditiontomethotrexateversusfilgotinibmonotherapyinpatientswithrheumatoidarthritiswithaninadequateresponsetomethotrexateamulticenterprospectiveopenlabelrandomizedcontrolledtrialfaithfulstudy |